WCN26-3995 Chronic Thrombotic Microangiopathy Induced by Long-Term Imatinib Therapy: A Case Report

Read full text Summarise with VIRAT
Authors: Mina Fujii, Goh Kodama, Tomoharu Takano, Sakuya Ito, Kei Fukami
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Imatinib, a tyrosine kinase inhibitor(TKI) targeting platelet-derived growth factor receptor (PDGFR), BCR-ABL and c-KIT, is generally regarded as a well-tolerated agent. However, prolonged inhibition of PDGFR signaling can lead to endothelial dysfunction and causes thrombotic microangiopathy (TMA) in rare cases. We report a case of chronic TMA that developed after 17 years of low-dose imatinib therapy for chronic myeloid leukemia (CML), emphasizing the potential for cumulative endothelial injury associated with extended exposure.

Fields of Study & Subjects

Complement system in diseases Chronic Myeloid Leukemia Treatments Platelet Disorders and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105739–105739
Publication date
25 March 2026
Language
EN